HC Wainwright Cuts MacroGenics (NASDAQ:MGNX) Price Target to $12.00

MacroGenics (NASDAQ:MGNX – Free Report) had its price target trimmed by HC Wainwright from $14.00 to $12.00 in a research note issued to investors on Monday, Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for MacroGenics’ Q4 2023 earnings at ($0.27) EPS, Q1 2024 […]

Leave a Reply

Your email address will not be published.

Previous post Ionis Pharmaceuticals (NASDAQ:IONS) Stock Rating Reaffirmed by William Blair
Next post JPMorgan Chase & Co. Lowers Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target to $10.00